| (-)-Naltrexone |
| (-)naltrexone |
| (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7,9,11(18)-trien-14-one |
| (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0^{1,13}.0^{5,17}.0^{7,18}]octadeca-7(18),8,10-trien-14-one |
| (1S,5R,13R,17S)-4-(cyclopropylmethyl)-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.0;{1,13}.0;{5,17}.0;{7,18}]octadeca-7(18),8,10-trien-14-one |
| (1S,5R,13R,17S)-4-(CYCLOPROPYLMETHYL)-10,17-DIHYDROXY-12-OXA-4-AZAPENTACYCLO[9.6.1.0(1),(1)(3).0?,(1)?.0?,(1)?]OCTADECA-7(18),8,10-TRIEN-14-ONE |
| (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-bis(oxidanyl)-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride |
| (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one |
| (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;hydrochloride |
| 16590-41-3 |
| 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxmorphinan-6-one, (5.alpha.)- |
| 17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-one |
| 17-(Cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6-one |
| 3,14-dihydroxy-17-(cyclopropylmethyl)-4,5alpha-epoxymorphinan-6-one |
| 5S6W795CQM |
| 88088-EP2270005A1 |
| 88088-EP2275420A1 |
| 88088-EP2298761A1 |
| 88088-EP2298776A1 |
| 88088-EP2305648A1 |
| AB00174152_17 |
| AB00174152-14 |
| AK192538 |
| AKOS015994596 |
| AN-12941 |
| BDBM50000787 |
| BDBM60212 |
| BIDD:GT0405 |
| BPBio1_000146 |
| BRD-K88172511-310-03-8 |
| BRN 3596648 |
| BSPBio_000132 |
| C07253 |
| CAS-16590-41-3 |
| CCRIS 3506 |
| Celupan |
| CHEBI:7465 |
| CHEMBL19019 |
| cid_5485201 |
| CS-0880 |
| cyclopropylmethyl(dihydroxy)[?]one |
| cyclopropylmethylnoroxymorphone |
| D05113 |
| D0PG8O |
| DB00704 |
| Depotrex |
| DQCKKXVULJGBQN-XFWGSAIBSA-N |
| DSSTox_CID_26313 |
| DSSTox_GSID_46313 |
| DSSTox_RID_81532 |
| DTXSID4046313 |
| EINECS 240-649-9 |
| EN-1639A [AS HYDROCHLORIDE] |
| FT-0696752 |
| GTPL1639 |
| HMS2089O11 |
| HS-0002 |
| HSDB 6750 |
| HY-76711 |
| IBS therapy, Pain Therapeutics |
| Irritable bowel syndrome therapy, Pain Therapeutics |
| LS-92094 |
| MCULE-7032963403 |
| MFCD00242996 |
| MolPort-004-920-221 |
| Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-alpha-epoxy-3,14-dihydroxy- |
| Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5alpha)- |
| Morphinan-6-one,17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5a)- |
| MorViva |
| N-Cyclopropylmethyl-14-hydroxydihydromorphinone |
| N-Cyclopropylmethylnoroxymorphone |
| Naltrel |
| Naltrexon |
| Naltrexona |
| Naltrexona [INN-Spanish] |
| naltrexone |
| Naltrexone (low-dose), Pain Therapeutics |
| Naltrexone (once-monthly controlled-release, Medisorb), Alkermes |
| Naltrexone (polymer microcapsule depot, opioid addiction/alcohol dependency), Biotek |
| naltrexone (ReVia) |
| Naltrexone (sustained release), DAS |
| Naltrexone (sustained release), elbion |
| Naltrexone (transdermal, alcohol/opioid dependence), Syntropharma |
| Naltrexone (USAN/INN) |
| Naltrexone [USAN:BAN:INN] |
| Naltrexone [USAN:INN:BAN] |
| Naltrexone base anhydrous |
| Naltrexone Depot |
| Naltrexone depot (injectable suspension), DrugAbuse Sciences |
| Naltrexone depot (injectable suspension), elbion |
| Naltrexone hydrochloride |
| Naltrexone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material |
| Naltrexonum |
| Naltrexonum [INN-Latin] |
| NCGC00024427-03 |
| NCGC00024427-04 |
| NCGC00024427-05 |
| NCGC00162274-02 |
| Nemexin |
| Opioid antagonists (irritable bowel syndrome), Pain Therapeutics |
| PDSP2_000847 |
| PL006614 |
| Prestwick0_000116 |
| Prestwick1_000116 |
| Prestwick2_000116 |
| Prestwick3_000116 |
| PTI-555 |
| PTI-901 |
| PubChem24168 |
| ReVia |
| SC-94535 |
| SCHEMBL34681 |
| SMP1_000206 |
| SPBio_002071 |
| Tox21_112007 |
| Tox21_112007_1 |
| UM-792 |
| UNII-5S6W795CQM |
| Vivitrex |
| Vivitrol (TN) |
| W-5099 |
| XR-NTX |
| ZINC1773 |
